Experimental Urooncology—New Insights from Basic and Translational Research

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (15 July 2022) | Viewed by 4547

Special Issue Editors

Department of Urology, Technical University Dresden, 01069 Dresden, Germany
Interests: prostate cancer; oncology; androgen receptor; stat-proteins; metabolism; tumor biology
Special Issues, Collections and Topics in MDPI journals
Department of Gynecology and Gynecological Oncology, University Hospital Bonn, 53127 Bonn, Germany
Interests: physical plasma medicine; translational molecular biology; wild life biology; veterinary research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Urological cancers have increased significantly in recent years and are expected to increase by 23% until 2030. This prediction includes cancers of the kidney, ureter, bladder, urethra, penis, prostate, and testicles. Recent clinical trials show encouraging results, and the prognosis of urological tumors can often be transformed from life-threatening to chronic disease. In particular, significant progress has been made in the treatment of locally advanced and metastatic prostate and renal cell cancer. However, despite significant research efforts and new treatment options, treatment failure and the development of resistance are still the most critical challenges in everyday clinical practice. Against this background, the development of new and complementary therapeutic strategies in urooncology is mandatory.

This Special Issue aims to publish original works and reviews that highlight the potential of experimental therapeutic approaches and strategies from basic and translational research targeting urological cancers.

Dr. Holger Hans Herman Erb
Dr. Matthias Stope
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urooncology
  • experimental therapy approaches
  • urology
  • drug targets
  • therapy resistance
  • translational urology

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 857 KiB  
Article
Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients
by Alexander Fichte, Angela Neumann, Katrin Weigelt, Juan Guzman, Thilo Jansen, Julia Keinert, Ginette Serrero, Binbin Yue, Robert Stöhr, Thomas Greither, Arndt Hartmann, Bernd Wullich, Helge Taubert, Sven Wach and Verena Lieb
Life 2022, 12(5), 732; https://0-doi-org.brum.beds.ac.uk/10.3390/life12050732 - 13 May 2022
Cited by 1 | Viewed by 1573
Abstract
Our study aimed to assess the applicability of miR-486 in combination with soluble GP88 protein as a diagnostic and/or predictive biomarker for prostate cancer (PCa) patients. miR-486 and GP88 levels in serum samples from 136 patients undergoing MRI-guided biopsy of the prostate were [...] Read more.
Our study aimed to assess the applicability of miR-486 in combination with soluble GP88 protein as a diagnostic and/or predictive biomarker for prostate cancer (PCa) patients. miR-486 and GP88 levels in serum samples from 136 patients undergoing MRI-guided biopsy of the prostate were assessed by qRT–PCR and ELISA, respectively. Of these, 86 patients received a histologically confirmed diagnosis of PCa. Neither marker showed an association with the diagnosis of cancer. PCa patients were separated based on (i) treatment into patients with active surveillance or patients with any type of curative treatment and (ii) age into elderly (>68 years) patients and younger patients (≤68 years). In elderly patients (N = 41) with the intention of curative treatment at optimized cut-off values, significantly higher GP88 levels (p = 0.018) and lower miR-486 levels (p = 0.014) were observed. The total PSA level and ISUP biopsy grade were used in a baseline model for predicting definitive therapy. The baseline model exhibited an area under the curve (AUC) of 0.783 (p = 0.005). The addition of the serum biomarkers miR-486 and GP88 to the baseline model yielded an improved model with an AUC of 0.808 (p = 0.002). Altogether, combined miR-486 and GP88 serum levels are associated with and are therefore suggested as supportive biomarkers for therapy decisions, particularly in elderly PCa patients. Full article
Show Figures

Figure 1

16 pages, 4653 KiB  
Article
Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm
by Beatriz Chaves Lourenço, Catarina Guimarães-Teixeira, Bianca C. T. Flores, Vera Miranda-Gonçalves, Rita Guimarães, Mariana Cantante, Paula Lopes, Isaac Braga, Joaquina Maurício, Carmen Jerónimo, Rui Henrique and João Lobo
Life 2022, 12(2), 264; https://0-doi-org.brum.beds.ac.uk/10.3390/life12020264 - 10 Feb 2022
Cited by 3 | Viewed by 2389
Abstract
TGCTs represent a model of curable disease afflicting especially young men. Defining tumor biological characteristics is crucial to increase current knowledge and tailor the best clinical management. Ki67, a potential prognostic marker, still exhibits heterogenous associations with patient outcomes, thus bringing the need [...] Read more.
TGCTs represent a model of curable disease afflicting especially young men. Defining tumor biological characteristics is crucial to increase current knowledge and tailor the best clinical management. Ki67, a potential prognostic marker, still exhibits heterogenous associations with patient outcomes, thus bringing the need of corroboration with larger cohorts in clinical practice. LSD1, an epigenetic enzyme, represents a future target for epigenetic drugs that may lower treatment-associated morbidity. This study aimed to assess Ki67/LSD1 immunoexpression across all TGCT histological subtypes and correlate it with clinicopathological features. Results were compared with an in silico analysis of the TCGA database. Immunohistochemistry for Ki67 and LSD1 was carried out in a cohort of 157 TGCT tumor samples and assessed using a digital pathology algorithm. LSD1 protein expression was explored in TGCT cell lines, including ATRA-differentiated clones. There was a significant positive correlation between Ki67 and LSD1 H-scores (rs = 0.182, p = 0.037). Ki67 positivity percentage and H-score were significantly higher in non-seminomas (p = 0.0316 and 0.0113, respectively). Expression was not significantly different according to clinicopathological features, including stage, IGCCCG prognosis-based system, or relapse/progression-free survival, which was corroborated by in silico analysis. Our study, making use of digital image analysis, does not confirm the utility of these biomarkers in a daily practice cohort. Although not affecting patient outcome in our cohort, LSD1 is expressed overall in TGCTs, suggesting sensitivity to LSD1 inhibitors. Full article
Show Figures

Figure 1

Back to TopTop